<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-0108</journal-id>
<journal-title><![CDATA[Revista Española de Enfermedades Digestivas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. esp. enferm. dig.]]></abbrev-journal-title>
<issn>1130-0108</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Patología Digestiva]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-01082018001000004</article-id>
<article-id pub-id-type="doi">10.17235/reed.2018.5605/2018</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación económica de una estrategia poblacional de tratamiento de la hepatitis C crónica con antivirales de acción directa]]></article-title>
<article-title xml:lang="en"><![CDATA[Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ibarrondo]]></surname>
<given-names><![CDATA[Oliver]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Baz]]></surname>
<given-names><![CDATA[Iván]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Juanbeltz]]></surname>
<given-names><![CDATA[Regina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A6"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[San-Miguel]]></surname>
<given-names><![CDATA[Ramón]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Casado]]></surname>
<given-names><![CDATA[Itziar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arrospide]]></surname>
<given-names><![CDATA[Arantzazu]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castilla]]></surname>
<given-names><![CDATA[Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Organización Sanitaria Integrada Alto Deba Unidad de Investigación AP-OSIs Gipuzkoa ]]></institution>
<addr-line><![CDATA[Mondragón, Guipúzcoa ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC)  ]]></institution>
<addr-line><![CDATA[Bilbao ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto de Investigación Biodonostia  ]]></institution>
<addr-line><![CDATA[San Sebastián, Donostia ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto de Salud Pública de Navarra - IdiSNA  ]]></institution>
<addr-line><![CDATA[Pamplona ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,CIBER Epidemiología y Salud Pública (CIBERESP)  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Complejo Hospitalario de Navarra - IdiSNA Departamento of Farmacia ]]></institution>
<addr-line><![CDATA[Pamplona ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>110</volume>
<numero>10</numero>
<fpage>621</fpage>
<lpage>628</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-01082018001000004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-01082018001000004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-01082018001000004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El elevado coste inicial de los antivirales frente a la hepatitis C impulsó el "Plan Estratégico Nacional para el abordaje de la hepatitis C en el Sistema Nacional de Salud". El objetivo de este estudio fue la evaluación económica de los dos primeros años de su aplicación en Navarra. Se modelizó con datos de cada paciente el cambio que la respuesta viral sostenida (RVS) produce en la historia natural de la hepatitis C frente a una alternativa sin tratamiento. Mediante simulación de eventos discretos se midió desde la perspectiva del Servicio Navarro de Salud el coste-efectividad y el impacto presupuestario de los pacientes tratados. Se trataron 656 pacientes y el 98% tuvo RVS. El coste medio de los tratamientos fue de 18.743 euros por paciente. La razón coste-efectividad incremental (RCEI) media con descuento fue de 5.346 euros por año de vida ajustado por calidad, siendo más eficiente a medida que aumentó el nivel de fibrosis, hasta alcanzar niveles de dominancia en la fibrosis grado 4. Los costes asociados a la enfermedad hepática crónica disminuyeron a medida que se fue expresando el beneficio del tratamiento. La aplicación del Plan Estratégico es coste-efectiva con una RCEI muy por debajo del umbral, ya que el coste del tratamiento se compensa en gran parte con el ahorro en gasto sanitario a largo plazo. El impacto presupuestario prevé un ahorro neto a partir del tercer año. Los dos parámetros determinantes fueron la disminución del precio del tratamiento y la RVS cercana al 100% de los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The high initial cost of antivirals against hepatitis C prompted development of the "Strategic Plan for Tackling Chronic Hepatitis C in the Spanish National Health System". The objective of this study was the economic evaluation of the first two years of its application in Navarre, Spain. The change in the natural history of hepatitis C produced by the sustained virological response (SVR) was compared to an alternative without treatment and modeled with patient-level data. By means of a discrete events simulation model, the cost-effectiveness and the budget impact analysis of the treatment program were measured from the perspective of the Navarre Health Service. Of 656 patients treated, 98% had SVR. The average cost of the treatments was 18,743 euros per patient. The incremental cost-effectiveness ratio (ICER) with discount was 5,346 euros per quality-adjusted life years, which became more efficient as the stage of fibrosis increased until it reached levels of dominance in stage 4 fibrosis. The associated costs for chronic liver disease decreased as the benefit of the treatment was expressed. The implementation of the Strategic Plan is cost-effective, with an ICER well below the threshold, since the cost of treatment is largely compensated by savings in long-term health expenditure. The budgetary impact foresees a net saving from the third year on. The two key parameters were the decrease in the price of the treatment and the SVR in nearly 100% of the patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Antivirales de acción directa]]></kwd>
<kwd lng="es"><![CDATA[Estudio coste-efectividad]]></kwd>
<kwd lng="es"><![CDATA[Hepatitis C crónica]]></kwd>
<kwd lng="es"><![CDATA[Años de vida ajustados por calidad]]></kwd>
<kwd lng="es"><![CDATA[Sofosbuvir]]></kwd>
<kwd lng="en"><![CDATA[Antiviral agents]]></kwd>
<kwd lng="en"><![CDATA[Cost-benefit analysis]]></kwd>
<kwd lng="en"><![CDATA[Chronic C hepatitis]]></kwd>
<kwd lng="en"><![CDATA[Quality-adjusted life years]]></kwd>
<kwd lng="en"><![CDATA[Sofosbuvir]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Razavi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Waked]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sarrazin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[J Viral Hepat]]></source>
<year>2014</year>
<volume>21</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>34-59</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[San Miguel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno-Ballester]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Blázquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Gut]]></source>
<year>2015</year>
<volume>64</volume>
<page-range>1277-88</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Side effects of therapy of hepatitis C and their management]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fried]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<source><![CDATA[Hepatology]]></source>
<year>2002</year>
<volume>36</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S237-44</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McHutchison]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Ware Jr]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bayliss]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity]]></article-title>
<collab>Hepatitis Interventional Therapy Group</collab>
<source><![CDATA[J Hepatol]]></source>
<year>2001</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>140-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blázquez-Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[San Miguel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[PharmacoEconomics]]></source>
<year>2013</year>
<volume>31</volume>
<page-range>919-31</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hézode]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fontaine]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dorival]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Gastroenterology]]></source>
<year>2014</year>
<volume>147</volume>
<page-range>132-142.e4</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawitz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mangia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wyles]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>368</volume>
<page-range>1878-87</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="book">
<collab>Secretaría General de Sanidad y Consumo</collab>
<source><![CDATA[Plan estratégico para el abordaje de la hepatitis C en el sistema nacional de salud]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Ministerio de Sanidad ]]></publisher-loc>
<publisher-name><![CDATA[Servicios Sociales y Consumo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Budget impact analysis-principles of good practice report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Mauskopf]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Augustovski]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Value Health]]></source>
<year>2014</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-1</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[On the Estimation of the Cost-Effectiveness Threshold Why, What, How?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallejo-Torres]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[García-Lorenzo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Castilla]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Value Health]]></source>
<year>2016</year>
<volume>19</volume>
<page-range>558-66</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gimeno-Ballester]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients]]></article-title>
<collab>O'Leary A</collab>
<source><![CDATA[Expert Rev Gastroenterol Hepatol]]></source>
<year>2017</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>85-93</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis Med]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mar-Barrutia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno-Ballester]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin (Barc)]]></source>
<year>2016</year>
<volume>146</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>61-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Using real-world data for coverage and payment decisions the ISPOR Real-World Data Task Force report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garrison Jr]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Neumann]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Erickson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Value Health]]></source>
<year>2007</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>326-35</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The prevalence of diagnosed and undiagnosed hepatitis C virus infection in Navarra, Spain, 2014-2016]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguinaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-González]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Modeling using discrete event simulation a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karnon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stahl]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Med Decis Making]]></source>
<year>2012</year>
<volume>32</volume>
<page-range>701-11</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Spanish recommendations on economic evaluation of health technologies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Bastida]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antoñanzas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2010</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>513-20</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Economic evaluation of the breast cancer screening programme in the Basque Country retrospective cost-effectiveness and budget impact analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrospide]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rue]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[van Ravesteyn]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Cancer]]></source>
<year>2016</year>
<volume>16</volume>
<page-range>344</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Younossi]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Saab]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2015</year>
<volume>41</volume>
<page-range>544-63</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Baz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ibarrondo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Expert Rev Gastroenterol Hepatol]]></source>
<year>2017</year>
<volume>0</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Los modelos de Markov probabilísticos en la evaluación económica de tecnologías sanitarias una guía práctica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antoñanzas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pradas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Gac Sanit]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>209-14</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Race but not Hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sawinski]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Forde]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Locke]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Kidney Int]]></source>
<year>2018</year>
<volume>93</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>706-15</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Determining the lifetime density function using a continuous approach]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Román]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Comas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmeister]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[J Epidemiol Community Health]]></source>
<year>2007</year>
<volume>61</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>923-5</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New protease inhibitors for the treatment of chronic hepatitis C a cost-effectiveness analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cipriano]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Holodniy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>2012</year>
<volume>156</volume>
<page-range>279-90</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="">
<source><![CDATA[RESOLUCIÓN 626/2014, de 5 de junio, del Director Gerente del Servicio Navarro de Salud-Osasunbidea, por la que se actualizan las tarifas por los servicios prestados por el Servicio Navarro de Salud-Osasunbidea]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grieve]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Gut]]></source>
<year>2006</year>
<volume>55</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1332-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Empirically calibrated model of hepatitis C virus infection in the United States]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salomon]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Weinstein]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Hammitt]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Epidemiol]]></source>
<year>2002</year>
<volume>156</volume>
<page-range>761-73</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[¿Qué es una tecnología sanitaria eficiente en España?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sacristán]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Del-Llano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Gac Sanit]]></source>
<year>2002</year>
<volume>16</volume>
<page-range>334-43</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chhatwal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Olivo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2016</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>551-67</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Value and innovation of direct-acting antivirals Long-term health outcomes of the strategic plan for management of hepatitis C in Spain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turnes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez Hernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Casado]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Enferm]]></source>
<year>2017</year>
<volume>109</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>809-17</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juanbeltz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Goñi Esarte]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Úriz-Otano]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<source><![CDATA[Postgrad Med]]></source>
<year>2017</year>
<volume>129</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>476-83</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Principios, métodos, y aplicaciones del análisis del impacto presupuestario en sanidad]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gisbert]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Barrios]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacoecon Spanish Res Artic]]></source>
<year>2005</year>
<volume>2</volume>
<page-range>65-79</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Morbidity and mortality in compensated cirrhosis type C a retrospective follow-up study of 384 patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fattovich]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Giustina]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Degos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Gastroenterology]]></source>
<year>1997</year>
<volume>112</volume>
<page-range>463-72</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Modelling methods for pharmacoeconomics and health technology assessment an overview and guide]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stahl]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacoeconomics]]></source>
<year>2008</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>131-48</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
